Lineage Cell Therapeutics, Inc. (LCTX)

Spirit Realty Capital Revenue

Lineage Cell Therapeutics had revenue of $1.50M in the quarter ending March 31, 2025, with 4.02% growth. This brings the company's revenue in the last twelve months to $9.56M, up 19.42% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.

• Revenue (ttm): $9.56M
• Revenue Growth: +19.42%
• P/S Ratio: 22.30
• Revenue / Employee: $124,117
• Employees: 77
• Market Cap: 230.64M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.50M	554.00K	6.19%
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.